Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease
East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during
antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor …
antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor …
[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS …
CJ Kim, MW Park, MC Kim, EH Choo, BH Hwang… - The Lancet, 2021 - thelancet.com
Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
[HTML][HTML] A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
DMF Claassens, GJA Vos, TO Bergmeijer… - … England Journal of …, 2019 - Mass Medical Soc
Background It is unknown whether patients undergoing primary percutaneous coronary
intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods …
intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods …
Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19
MJ Mina, TE Peto, M García-Fiñana, MG Semple… - The Lancet, 2021 - thelancet.com
1 Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
Bleeding avoidance strategies in percutaneous coronary intervention
For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease
M Nakamura, K Kimura, T Kimura, M Ishihara… - Circulation …, 2020 - jstage.jst.go.jp
In 2019, the Japanese Circulation Society published 2 guidelines in the field of coronary
artery disease (CAD):(1) a guideline for acute coronary syndrome (ACS) that integrated …
artery disease (CAD):(1) a guideline for acute coronary syndrome (ACS) that integrated …
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE …
Summary Background A potent P2Y12 inhibitor-based dual antiplatelet therapy is
recommended for up to 1 year in patients with acute coronary syndrome receiving …
recommended for up to 1 year in patients with acute coronary syndrome receiving …